AZNCF:OTO-AstraZeneca Plc (USD)

COMMON STOCK | Drug Manufacturers - General | OTC Pink

Last Closing

USD 149.245

Change

0.00 (0.00)%

Market Cap

USD 72.36B

Volume

1.71K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AstraZeneca PLC is a biopharmaceutical company. It is engaged in the discovery and development of new products, which are then manufactured, marketed and sold.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
NVSEF Novartis AG

N/A

USD 206.77B
RHHVF Roche Holding AG Participation

N/A

USD 203.39B
RHHBF Roche Holding AG

N/A

USD 203.39B
RHHBY Roche Holding Ltd ADR

N/A

USD 202.85B
SNYNF Sanofi

N/A

USD 124.97B
GLAXF GSK plc

N/A

USD 94.22B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 67.24B
DSKYF Daiichi Sankyo Company Limited

N/A

USD 65.79B
CHGCY Chugai Pharmaceutical Co Ltd A..

N/A

USD 52.77B
CHGCF Chugai Pharmaceutical Co. Ltd

N/A

USD 50.26B

ETFs Containing AZNCF

INAG 1.34 % 0.00 %

N/A

N/A
DBAW Xtrackers MSCI All World .. 0.00 % 0.41 %

N/A

USD 0.16B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.00% 88% B+ 68% D+
Dividend Return 1.46% 55% F 38% F
Total Return 12.47% 91% A- 69% C-
Trailing 12 Months  
Capital Gain 0.50% 66% D+ 62% D
Dividend Return 1.91% 33% F 25% F
Total Return 2.42% 64% D 61% D-
Trailing 5 Years  
Capital Gain 98.84% 94% A 88% B+
Dividend Return 16.34% 73% C 55% F
Total Return 115.18% 94% A 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 11.59% 88% B+ 58% F
Dividend Return 13.77% 79% B- 57% F
Total Return 2.18% 56% F 48% F
Risk Return Profile  
Volatility (Standard Deviation) 12.15% 100% F 95% A
Risk Adjusted Return 113.34% 100% F 99% N/A
Market Capitalization 72.36B 100% F 100% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.